Livanova Plc OR Sh (LIVN)

$35.58 +0.51 (1.45%)
Market Cap 1.93B
Revenue (ttm) 1.25B
Net Income (ttm) 63.23M
EPS (ttm) N/A
PE Ratio 11.57
Forward PE 11.10
Profit Margin 5.04%
Debt to Equity Ratio 0.48
Volume 614,500
Avg Vol 786,756
Day's Range N/A - N/A
Shares Out 54.35M
Stochastic %K 62%
Beta 0.90
Analysts Strong Sell
Price Target $61.75

Latest News on LIVN

LivaNova to Announce First-Quarter 2025 Results

Mar 26, 2025, 8:00 AM EDT - 26 days ago

LivaNova to Announce First-Quarter 2025 Results

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 PM EST - 7 weeks ago

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

Feb 25, 2025, 6:00 AM EST - 7 weeks ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

Feb 21, 2025, 9:00 AM EST - 2 months ago

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Jan 21, 2025, 9:00 AM EST - 3 months ago

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Dec 18, 2024, 8:30 AM EST - 4 months ago

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 9:00 AM EST - 4 months ago

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Nov 14, 2024, 9:00 AM EST - 5 months ago

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Nov 11, 2024, 4:05 PM EST - 5 months ago

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 2:30 PM EDT - 6 months ago

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova Reports Third-Quarter 2024 Results

Oct 30, 2024, 6:00 AM EDT - 6 months ago

LivaNova Reports Third-Quarter 2024 Results

LivaNova: Economics Should Start Making Sustained Improvements

Oct 18, 2024, 3:45 AM EDT - 6 months ago

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova Appoints Susan Podlogar as a New Director

Oct 8, 2024, 9:00 AM EDT - 6 months ago

LivaNova Appoints Susan Podlogar as a New Director

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Oct 4, 2024, 11:59 AM EDT - 7 months ago

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

LivaNova to Announce Third-Quarter 2024 Results

Sep 25, 2024, 9:00 AM EDT - 7 months ago

LivaNova to Announce Third-Quarter 2024 Results

LivaNova to Present at the Baird Global Healthcare Conference

Aug 19, 2024, 9:00 AM EDT - 8 months ago

LivaNova to Present at the Baird Global Healthcare Conference

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 1:57 PM EDT - 9 months ago

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

LivaNova Reports Second-Quarter 2024 Results

Jul 31, 2024, 6:00 AM EDT - 9 months ago

LivaNova Reports Second-Quarter 2024 Results

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

Jun 24, 2024, 6:24 PM EDT - 10 months ago

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

LivaNova to Announce Second-Quarter 2024 Results

Jun 18, 2024, 9:00 AM EDT - 10 months ago

LivaNova to Announce Second-Quarter 2024 Results

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

Jun 6, 2024, 9:00 AM EDT - 11 months ago

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

LivaNova to Present at the Goldman Sachs Healthcare Conference

May 23, 2024, 9:00 AM EDT - 11 months ago

LivaNova to Present at the Goldman Sachs Healthcare Conference

LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript

May 1, 2024, 10:56 AM EDT - 1 year ago

LivaNova PLC (LIVN) Q1 2024 Earnings Call Transcript

LivaNova Reports First-Quarter 2024 Results

May 1, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports First-Quarter 2024 Results

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

Apr 30, 2024, 9:00 AM EDT - 1 year ago

LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

Apr 25, 2024, 4:03 PM EDT - 1 year ago

LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

LivaNova to Announce First-Quarter 2024 Results

Mar 21, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce First-Quarter 2024 Results

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Mar 20, 2024, 9:00 AM EDT - 1 year ago

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

Mar 5, 2024, 9:55 PM EST - 1 year ago

LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

Mar 4, 2024, 4:44 PM EST - 1 year ago

LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

LivaNova PLC (LIVN) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 10:36 AM EST - 1 year ago

LivaNova PLC (LIVN) Q4 2023 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

Feb 21, 2024, 6:00 AM EST - 1 year ago

LivaNova Reports Fourth-Quarter and Full-Year 2023 Results

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

Feb 5, 2024, 8:00 AM EST - 1 year ago

LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

LivaNova to Wind Down Advanced Circulatory Support Business Unit

Jan 8, 2024, 8:30 AM EST - 1 year ago

LivaNova to Wind Down Advanced Circulatory Support Business Unit

LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

Jan 4, 2024, 9:00 AM EST - 1 year ago

LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

LivaNova: Reaching End Of RECOVER And ANTHEM

Dec 26, 2023, 6:00 PM EST - 1 year ago

LivaNova: Reaching End Of RECOVER And ANTHEM

LivaNova to Present at the Piper Sandler Healthcare Conference

Nov 9, 2023, 9:00 AM EST - 1 year ago

LivaNova to Present at the Piper Sandler Healthcare Conference

LivaNova PLC (LIVN) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 1:26 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q3 2023 Earnings Call Transcript

LivaNova Reports Third-Quarter 2023 Results

Nov 1, 2023, 6:00 AM EDT - 1 year ago

LivaNova Reports Third-Quarter 2023 Results

LivaNova to Present at the Stifel and Wolfe Healthcare Conferences

Oct 25, 2023, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Stifel and Wolfe Healthcare Conferences

LivaNova Board Appoints J. Christopher Barry as New Director

Oct 6, 2023, 8:30 AM EDT - 1 year ago

LivaNova Board Appoints J. Christopher Barry as New Director

LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

Sep 21, 2023, 7:00 AM EDT - 1 year ago

LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

LivaNova to Announce Third-Quarter 2023 Results

Sep 20, 2023, 9:00 AM EDT - 1 year ago

LivaNova to Announce Third-Quarter 2023 Results

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Aug 30, 2023, 4:05 PM EDT - 1 year ago

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

LivaNova PLC (LIVN) Q2 2023 Earnings Call Transcript

Jul 26, 2023, 1:10 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q2 2023 Earnings Call Transcript

LivaNova Reports Second-Quarter 2023 Results

Jul 26, 2023, 6:00 AM EDT - 1 year ago

LivaNova Reports Second-Quarter 2023 Results

LivaNova to Announce Second-Quarter 2023 Results

Jun 14, 2023, 9:00 AM EDT - 2 years ago

LivaNova to Announce Second-Quarter 2023 Results

LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study

Jun 13, 2023, 9:00 AM EDT - 2 years ago

LivaNova Announces 150th Bipolar Depression Patient Randomized in RECOVER Clinical Study